nach oben

Current Pain and Headache Reports

Erschienen in:

01.01.2018 | Secondary Headache (M Robbins, Section Editor)

Giant Cell Arteritis: Practical Pearls and Updates

verfasst von: Swati Pradeep, Jonathan H. Smith

Erschienen in: Current Pain and Headache Reports | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

The purpose of this review is to summarize recent updates and distill practical points from the literature which can be applied to the care of patients with suspected and confirmed giant cell arteritis (GCA).

Recent Findings

Contemporary thinking implicates a fundamental failure of T regulatory cell function in GCA pathophysiology, representing opportunity for novel therapeutic avenues. Tocilizumab has become the first Food and Drug Administration-approved treatment for GCA following demonstration of efficacy and safety in a phase 3 clinical trial.

Summary

There have been significant parallel advances in both our understanding of GCA pathophysiology and treatment. Tocilizumab, and other agents currently under investigation in phase 2 and 3 clinical trials, presents a new horizon of hope for both disease remission and avoidance of glucocorticoid-related complications.

Smith JH, Swanson JW. Giant cell arteritis. Headache. 2014;54(8):1273–89. https://doi.org/10.1111/head.12425.CrossRefPubMed

Salvarani C, Gabriel SE, O’Fallon WM, Hunder GG. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med. 1995;123(3):192–4. https://doi.org/10.7326/0003-4819-123-3-199508010-00006.CrossRefPubMed

Aiello PD, Trautmann JC, McPhee TJ, Kunselman AR, Hunder GG. Visual prognosis in giant cell arteritis. Ophthalmology. 1993;100(4):550–5. https://doi.org/10.1016/S0161-6420(93)31608-8.CrossRefPubMed

Hill CL, Black RJ, Nossent JC, Ruediger C, Nguyen L, Ninan JV, et al. Risk of mortality in patients with giant cell arteritis: a systematic review and meta-analysis. Semin Arthritis Rheum. 2017;46(4):513–9. https://doi.org/10.1016/j.semarthrit.2016.08.015.CrossRefPubMed

Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122–8.CrossRefPubMed

Ma-Krupa W, Jeon MS, Spoerl S, Tedder TF, Goronzy JJ, Weyand CM. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med. 2004;199(2):173–83. https://doi.org/10.1084/jem.20030850.CrossRefPubMedPubMedCentral

Watanabe R, Hosgur E, Zhang H, Wen Z, Berry G, Goronzy JJ, et al. Pro-inflammatory and anti-inflammatory T cells in giant cell arteritis. Joint Bone Spine. 2017;84(4):421–6. https://doi.org/10.1016/j.jbspin.2016.07.005.CrossRefPubMed

•• Wen Z, Shimojima Y, Shirai T, Li Y, Ju J, Yang Z, et al. NADPH oxidase deficiency underlies dysfunction of aged CD8+ Tregs. J Clin Invest. 2016;126(5):1953–1967. CD8+ T regulatory cells appear to be deficient in patients with GCA, independent of treatment, potentially allowing for observed CD4+ T cell hyperimmunity. https://doi.org/10.1172/JCI84181.CrossRefPubMedPubMedCentral

Miyabe C, Miyabe Y, Strle K, Kim ND, Stone JH, Luster AD, et al. An expanded population of pathogenic regulatory T cells in giant cell arteritis is abrogated by IL-6 blockade therapy. Ann Rheum Dis. 2017;76(5):898–905. https://doi.org/10.1136/annrheumdis-2016-210070.CrossRefPubMed

10.

Weyand CM, Younge BR, Goronzy JJ. IFN-gamma and IL-17: the two faces of T-cell pathology in giant cell arteritis. Curr Opin Rheumatol. 2011;23(1):43–9. https://doi.org/10.1097/BOR.0b013e32833ee946.CrossRefPubMedPubMedCentral

11.

Samson M, Corbera-Bellalta M, Audia S, Planas-Rigol E, Martin L, Cid MC, et al. Recent advances in our understanding of giant cell arteritis pathogenesis. Autoimmun Rev. 2017;16(8):833–44. https://doi.org/10.1016/j.autrev.2017.05.014.CrossRefPubMed

12.

Watad A, Bragazzi NL, Adawi M, Amital H, Toubi E, Porat BS, et al. Autoimmunity in the elderly: insights from basic science and clinics—a mini-review. Gerontology. 2017;63(6):515–23. https://doi.org/10.1159/000478012.CrossRefPubMed

13.

Lee HY, Oh BH. Aging and arterial stiffness. Circ J. 2010;74(11):2257–62. https://doi.org/10.1253/circj.CJ-10-0910.CrossRefPubMed

14.

Wang M, Monticone RE, Lakatta EG. Arterial aging: a journey into subclinical arterial disease. Curr Opin Nephrol Hypertens. 2010;19(2):201–7. https://doi.org/10.1097/MNH.0b013e3283361c0b.CrossRefPubMedPubMedCentral

15.

Carmona FD, Vaglio A, Mackie SL, Hernández-Rodríguez J, Monach PA, Castañeda S, et al. A genome-wide association study identifies risk alleles in plasminogen and P4HA2 associated with giant cell arteritis. Am J Hum Genet. 2017;100(1):64–74. https://doi.org/10.1016/j.ajhg.2016.11.013.CrossRefPubMed

16.

Gilden D, Nagel MA. Varicella zoster virus triggers the immunopathology of giant cell arteritis. Curr Opin Rheumatol. 2016;28(4):376–82. https://doi.org/10.1097/BOR.0000000000000292.CrossRefPubMedPubMedCentral

17.

Prior JA, Ranjbar H, Belcher J, Mackie SL, Helliwell T, Liddle J, et al. Diagnostic delay for giant cell arteritis—a systematic review and meta-analysis. BMC Med. 2017;15(1):120. https://doi.org/10.1186/s12916-017-0871-z.CrossRefPubMedPubMedCentral

18.

Caselli RJ, Hunder GG, Whisnant JP. Neurologic disease in biopsy-proven giant cell (temporal) arteritis. Neurology. 1988;38(3):352–9. https://doi.org/10.1212/WNL.38.3.352.CrossRefPubMed

19.

Jimenez-Jimenez FJ, Garcia-Albea E, Zurdo M, Martinez-Onsurbe P, Ruiz de Villaespesa A. Giant cell arteritis presenting as cluster headache. Neurology. 1998;51(6):1767–8. https://doi.org/10.1212/WNL.51.6.1767.CrossRefPubMed

20.

Rozen TD. Brief sharp stabs of head pain and giant cell arteritis. Headache. 2010;50(9):1516–9. https://doi.org/10.1111/j.1526-4610.2010.01718.x.CrossRefPubMed

21.

Solomon S, Cappa KG. The headache of temporal arteritis. J Am Geriatr Soc. 1987;35(2):163–5. https://doi.org/10.1111/j.1532-5415.1987.tb01348.x.CrossRefPubMed

22.

Smetana GW, Shmerling RH. Does this patient have temporal arteritis? JAMA. 2002;287(1):92–101. https://doi.org/10.1001/jama.287.1.92.CrossRefPubMed

23.

Miller NR. Visual manifestations of temporal arteritis. Rheum Dis Clin N Am. 2001;27(4):781–797, vi. https://doi.org/10.1016/S0889-857X(05)70235-0.CrossRef

24.

Gonzalez-Gay MA, Vazquez-Rodriguez TR, Gomez-Acebo I, Pego-Reigosa R, Lopez-Diaz MJ, Vazquez-Triñanes MC, et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine (Baltimore). 2009;88(4):227–35. https://doi.org/10.1097/MD.0b013e3181af4518.CrossRef

25.

Wilkinson IM, Russell RW. Arteries of the head and neck in giant cell arteritis. A pathological study to show the pattern of arterial involvement. Arch Neurol. 1972;27(5):378–91. https://doi.org/10.1001/archneur.1972.00490170010003.CrossRefPubMed

26.

Ungprasert P, Wijarnpreecha K, Koster MJ, Thongprayoon C, Warrington KJ. Cerebrovascular accident in patients with giant cell arteritis: a systematic review and meta-analysis of cohort studies. Semin Arthritis Rheum. 2016;46(3):361–6. https://doi.org/10.1016/j.semarthrit.2016.07.005.CrossRefPubMed

27.

Pascuzzi RM, Roos KL, Davis TE Jr. Mental status abnormalities in temporal arteritis: a treatable cause of dementia in the elderly. Arthritis Rheum. 1989;32(10):1308–11. https://doi.org/10.1002/anr.1780321017.CrossRefPubMed

28.

Schon F. Involvement of smell and taste in giant cell arteritis. J Neurol Neurosurg Psychiatry. 1988;51(12):1594. https://doi.org/10.1136/jnnp.51.12.1594.CrossRefPubMedPubMedCentral

29.

Dimant J, Grob D, Brunner NG. Ophthalmoplegia, ptosis, and miosis in temporal arteritis. Neurology. 1980;30(10):1054–8. https://doi.org/10.1212/WNL.30.10.1054.CrossRefPubMed

30.

Jay WM, Nazarian SM. Bilateral sixth nerve pareses with temporal arteritis and diabetes. J Clin Neuroophthalmol. 1986;6(2):91–5.PubMed

31.

Tamhankar MA, Biousse V, Ying GS, Prasad S, Subramanian PS, Lee MS, et al. Isolated third, fourth, and sixth cranial nerve palsies from presumed microvascular versus other causes: a prospective study. Ophthalmology. 2013;120(11):2264–9. https://doi.org/10.1016/j.ophtha.2013.04.009.CrossRefPubMed

32.

Roomet A, Allen JS. Temporal arteritis heralded by facial nerve palsy. JAMA. 1974;228(7):870–1. https://doi.org/10.1001/jama.1974.03230320040027.CrossRefPubMed

33.

Healey LA, Wilske KR. Presentation of occult giant cell arteritis. Arthritis Rheum. 1980;23(6):641–3. https://doi.org/10.1002/art.1780230605.CrossRefPubMed

34.

Calamia KT, Hunder GG. Giant cell arteritis (temporal arteritis) presenting as fever of undetermined origin. Arthritis Rheum. 1981;24(11):1414–8. https://doi.org/10.1002/art.1780241113.CrossRefPubMed

35.

Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. Arthritis Rheum. 2003;48(12):3522–31. https://doi.org/10.1002/art.11353.CrossRefPubMed

36.

Garcia-Martinez A, Hernandez-Rodriguez J, Arguis P, et al. Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. Arthritis Rheum. 2008;59(3):422–30. https://doi.org/10.1002/art.23315.CrossRefPubMed

37.

Gonzalez-Gay MA, Garcia-Porrua C, Pineiro A, Pego-Reigosa R, Llorca J, Hunder GG. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine (Baltimore). 2004;83(6):335–41. https://doi.org/10.1097/01.md.0000145366.40805.f8.CrossRef

38.

Prieto-Gonzalez S, Arguis P, Garcia-Martinez A, et al. Large vessel involvement in biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients using CT angiography. Ann Rheum Dis. 2012;71(7):1170–6. https://doi.org/10.1136/annrheumdis-2011-200865.CrossRefPubMed

39.

Grayson PC, Maksimowicz-McKinnon K, Clark TM, Tomasson G, Cuthbertson D, Carette S, et al. Distribution of arterial lesions in Takayasu’s arteritis and giant cell arteritis. Ann Rheum Dis. 2012;71(8):1329–34. https://doi.org/10.1136/annrheumdis-2011-200795.CrossRefPubMedPubMedCentral

40.

Myklebust G, Gran JT. A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: clinical and laboratory manifestations at onset of disease and at the time of diagnosis. Br J Rheumatol. 1996;35(11):1161–8.CrossRefPubMed

41.

Grayson PC, Tomasson G, Cuthbertson D, et al. Association of vascular physical examination findings and arteriographic lesions in large vessel vasculitis. J Rheumatol. 2012;39(2):303–9. https://doi.org/10.3899/jrheum.110652.CrossRefPubMed

42.

Tsianakas A, Ehrchen JM, Presser D, Fischer T, Kruse-Loesler B, Luger TA, et al. Scalp necrosis in giant cell arteritis: case report and review of the relevance of this cutaneous sign of large-vessel vasculitis. J Am Acad Dermatol. 2009;61(4):701–6. https://doi.org/10.1016/j.jaad.2008.11.913.CrossRefPubMed

43.

Husein-Elahmed H, Callejas-Rubio JL, Rios-Fernandez R, Ortego-Centeno N. Tongue infarction as first symptom of temporal arteritis. Rheumatol Int. 2012;32(3):799–800. https://doi.org/10.1007/s00296-009-1355-z.CrossRefPubMed

44.

Kermani TA, Schmidt J, Crowson CS, Ytterberg SR, Hunder GG, Matteson e, et al. Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum. 2012;41(6):866–71. https://doi.org/10.1016/j.semarthrit.2011.10.005.CrossRefPubMed

45.

Salvarani C, Hunder GG. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurrence in a population-based study. Arthritis Rheum. 2001;45(2):140–5. https://doi.org/10.1002/1529-0131(200104)45:2<140::AID-ANR166>3.0.CO;2-2.CrossRefPubMed

46.

Miller A, Green M, Robinson D. Simple rule for calculating normal erythrocyte sedimentation rate. Br Med J (Clin Res Ed). 1983:286–66.

47.

Gonzalez-Gay MA, Lopez-Diaz MJ, Barros S, Garcia-Porrua C, Sanchez-Andrade A, Paz-Carreira J, et al. Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. Medicine (Baltimore). 2005;84(5):277–90. https://doi.org/10.1097/01.md.0000180043.19285.54.CrossRef

48.

Mahr A, Saba M, Kambouchner M, Polivka M, Baudrimont M, Brochériou I, et al. Temporal artery biopsy for diagnosing giant cell arteritis: the longer, the better? Ann Rheum Dis. 2006;65(6):826–8. https://doi.org/10.1136/ard.2005.042770.CrossRefPubMedPubMedCentral

49.

Achkar AA, Lie JT, Hunder GG, O’Fallon WM, Gabriel SE. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med. 1994;120(12):987–92. https://doi.org/10.7326/0003-4819-120-12-199406150-00003.CrossRefPubMed

50.

Narvaez J, Bernad B, Roig-Vilaseca D, et al. Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. Semin Arthritis Rheum. 2007;37(1):13–9. https://doi.org/10.1016/j.semarthrit.2006.12.005.CrossRefPubMed

51.

Jia L, Couce M, Barnholtz-Sloan JS, Cohen ML. Is all inflammation within temporal artery biopsies temporal arteritis? Hum Pathol. 2016;57:17–21. https://doi.org/10.1016/j.humpath.2016.07.004.CrossRefPubMed

52.

Duhaut P, Pinede L, Bornet H, Demolombe-Rague S, Dumontet C, Ninet J, et al. Biopsy proven and biopsy negative temporal arteritis: differences in clinical spectrum at the onset of the disease. Groupe de Recherche sur l'Arterite a Cellules Geantes. Ann Rheum Dis. 1999;58(6):335–41. https://doi.org/10.1136/ard.58.6.335.CrossRefPubMedPubMedCentral

53.

Arida A, Kyprianou M, Kanakis M, Sfikakis PP. The diagnostic value of ultrasonography-derived edema of the temporal artery wall in giant cell arteritis: a second meta-analysis. BMC Musculoskelet Disord. 2010;11(1):44. https://doi.org/10.1186/1471-2474-11-44.CrossRefPubMedPubMedCentral

54.

Bley TA, Weiben O, Uhl M, Vaith P, Schmidt D, Warnatz K, et al. Assessment of the cranial involvement pattern of giant cell arteritis with 3T magnetic resonance imaging. Arthritis Rheum. 2005;52(8):2470–7. https://doi.org/10.1002/art.21226.CrossRefPubMed

55.

Bley TA, Wieben O, Uhl M, Thiel J, Schmidt D, Langer M. High-resolution MRI in giant cell arteritis: imaging of the wall of the superficial temporal artery. AJR Am J Roentgenol. 2005;184(1):283–7. https://doi.org/10.2214/ajr.184.1.01840283.CrossRefPubMed

56.

Geiger J, Ness T, Uhl M, Lagrèze WA, Vaith P, Langer M, et al. Involvement of the ophthalmic artery in giant cell arteritis visualized by 3T MRI. Rheumatology (Oxford). 2009;48(5):537–41. https://doi.org/10.1093/rheumatology/kep011.CrossRef

57.

Besson FL, Parienti JJ, Bienvenu B, Prior JO, Costo S, Bouvard G, et al. Diagnostic performance of 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011;38(9):1764–72. https://doi.org/10.1007/s00259-011-1830-0.CrossRefPubMed

58.

Hauenstein C, Reinhard M, Geiger J, Markl M, Hetzel A, Treszl A, et al. Effects of early corticosteroid treatment on magnetic resonance imaging and ultrasonography findings in giant cell arteritis. Rheumatology (Oxford). 2012;51(11):1999–2003. https://doi.org/10.1093/rheumatology/kes153.CrossRef

59.

Chmelewski WL, McKnight KM, Agudelo CA, Wise CM. Presenting features and outcomes in patients undergoing temporal artery biopsy. A review of 98 patients. Arch Intern Med. 1992;152(8):1690–5. https://doi.org/10.1001/archinte.1992.00400200120022.CrossRefPubMed

60.

Roth AM, Milsow L, Keltner JL. The ultimate diagnoses of patients undergoing temporal artery biopsies. Arch Ophthalmol. 1984;102(6):901–3. https://doi.org/10.1001/archopht.1984.01040030721028.CrossRefPubMed

61.

Nishino H, DeRemee RA, Rubino FA, Parisi JE. Wegener’s granulomatosis associated with vasculitis of the temporal artery: report of five cases. Mayo Clin Proc. 1993;68(2):115–21. https://doi.org/10.1016/S0025-6196(12)60157-8.CrossRefPubMed

62.

Genereau T, Martin A, Lortholary O, Noel V, Guillevin L. Temporal arteritis symptoms in a patient with hepatitis C virus associated type II cryoglobulinemia and small vessel vasculitis. J Rheumatol. 1998;25(1):183–5.PubMed

63.

Haugeberg G, Bie R, Johnsen V. Vasculitic changes in the temporal artery in polyarteritis nodosa. Scand J Rheumatol. 1997;26(5):383–5. https://doi.org/10.3109/03009749709065704.CrossRefPubMed

64.

Dasgupta B, Borg FA, Hassan N, Alexander L, Barraclough K, Bourke B, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford). 2010;49(8):1594–7. https://doi.org/10.1093/rheumatology/keq039a.CrossRef

65.

Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009;68(3):318–23. https://doi.org/10.1136/ard.2008.088351.CrossRefPubMed

66.

Ray-Chaudhuri N, Kine DA, Tijani SO, et al. Effect of prior steroid treatment on temporal artery biopsy findings in giant cell arteritis. Br J Ophthalmol. 2002;86(5):530–2. https://doi.org/10.1136/bjo.86.5.530.CrossRefPubMedPubMedCentral

67.

Hall S, Persellin S, Lie JT, O’Brien PC, Kurland LT, Hunder GG. The therapeutic impact of temporal artery biopsy. Lancet. 1983;2(8361):1217–20.CrossRefPubMed

68.

•• Kermani TA, Warrington KJ, Cuthbertson D, Carette S, Hoffman GS, Khalidi NA, et al. Disease relapses among patients with giant cell arteritis: a prospective, longitudinal cohort study. J Rheumatol. 2015;42(7):1213–1217. Approximately 1-in-5 GCA relapses will be associated with normal serum inflammatory markers. Headache and polymyalgia rheumatica are the most common symptoms at relapse presentation, with headache only uncommonly being an isolated symptom. https://doi.org/10.3899/jrheum.141347.CrossRefPubMedPubMedCentral

69.

Proven A, Gabriel SE, Orces C, O’Fallon WM, Hunder GG. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum. 2003;49(5):703–8. https://doi.org/10.1002/art.11388.CrossRefPubMed

70.

Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res (Hoboken). 2010;62(11):1515–26. https://doi.org/10.1002/acr.20295.CrossRef

71.

•• Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med. 2017;377(4):317–328. Subcutaneous tocilizumab given either weekly or every other week has been convincingly demonstrated in a phase 3 clinical trial to improve the rates of 52-week glucocorticoid-free remission in patients with GCA, leading to it being the first FDA-approved treatment for the disorder. https://doi.org/10.1056/NEJMoa1613849.CrossRefPubMed

72.

Langford CA, Cuthbertson D, Ytterberg SR, Khalidi N, Monach PA, Carette S, et al. A randomized, double-blind trial of abatacept (CTLA-4Ig) for the treatment of Giant cell arteritis. Arthritis Rheumatol. 2017;69(4):837–45. https://doi.org/10.1002/art.40044.CrossRefPubMed

73.

Mahr AD, Jover JA, Spiera RF, Hernández-García C, Fernández-Gutiérrez B, LaValley MP, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum. 2007;56(8):2789–97. https://doi.org/10.1002/art.22754.CrossRefPubMed

74.

Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum. 1993;36(9):1286–94. https://doi.org/10.1002/art.1780360913.CrossRefPubMed

75.

Villiger PM, Adler S, Kuchen S, Wermelinger F, Dan D, Fiege V, et al. Tocilizumab for induction and maintenance of remission in giant cell arteritis: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2016;387(10031):1921–7. https://doi.org/10.1016/S0140-6736(16)00560-2.CrossRefPubMed

76.

Guillevin L, Regent A. Treating giant-cell arteritis: is IL-6 the cytokine to target? Lancet. 2016;387(10031):1882–3. https://doi.org/10.1016/S0140-6736(16)30183-0.CrossRefPubMed

Titel: Giant Cell Arteritis: Practical Pearls and Updates
verfasst von: Swati Pradeep
Jonathan H. Smith
Publikationsdatum: 01.01.2018
Verlag: Springer US
Erschienen in: Current Pain and Headache Reports / Ausgabe 1/2018
Print ISSN: 1531-3433
Elektronische ISSN: 1534-3081
DOI: https://doi.org/10.1007/s11916-018-0655-y

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

hier abonnieren

Springer Medizin

Giant Cell Arteritis: Practical Pearls and Updates

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet AINS

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Häufigste Gründe für Brustschmerzen bei Kindern

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update AINS

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Medical Cannabis for Neuropathic Pain

Image Guidance Technologies for Interventional Pain Procedures: Ultrasound, Fluoroscopy, and CT

Medical Marijuana: Current Concepts, Pharmacological Actions of Cannabinoid Receptor Mediated Activation, and Societal Implications

Utility of Radionuclide Bone Scintigraphy in Complex Regional Pain Syndrome

Radio Frequency Ablation and Pulsed Radiofrequency for Treating Peripheral Neuralgias

Neuroimaging Findings in Patients with Medication Overuse Headache

Neu im Fachgebiet AINS

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Häufigste Gründe für Brustschmerzen bei Kindern

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

Endlich: Zi zeigt, mit welchen PVS Praxen zufrieden sind

Update AINS